Skip to content

Search...

About
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- Who we are
- FAQ
- Annual Report
Why New TB Drugs
R&D
Access
News

Search...

About
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- Who we are
- FAQ
- Annual Report
Why New TB Drugs
R&D
Access
News

Search...

About
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- Who we are
- FAQ
- Annual Report
Why New TB Drugs
R&D
Access
News

Search...

About
- Our Mission
- Donors
- Board of Directors
- Advisory Boards
- Staff
- Careers
- Who we are
- FAQ
- Annual Report
Why New TB Drugs
R&D
Access
News

Our Pipeline

Portfolio
Compounds
Regimens
Partners
Trials

TB Alliance works with a diverse network of global partners, including the world’s leading pharmaceutical developers, academic institutions, and research institutes. The following organizations are TB Alliance research and development partners.

AbbVie

AIDS Clinical Trial Group (ACTG)

Bill & Melinda Gates Foundation

Bill & Melinda Gates Medical Research Institute

ERA4TB

Evotec

Foundation for Neglected Disease Research

GlaxoSmithKline

Global Health Drug Discovery Institute

Harvard University

Hongqi Pharmaceutical

IMPAACT

Institute of Materia Medica

International Tuberculosis Research Center (ITRC)

Janssen Pharmaceuticals

Johns Hopkins University

KNCV Tuberculosefonds

Korea International Cooperation Agency (KOICA)

Lgenia

Lupin

Macleods

Médecins Sans Frontières (MSF) Amsterdam Office

Medical Research Council at University College London

National Center for Advancing Translational Sciences (NCATS)

Otsuka Pharmaceutical

PanACEA

Qurient Therapeutics

Radboud University

Schrodinger

TB Drug Accelerator Program

Texas A&M University

The Aurum Institute

UNITE4TB Consortium

University College London

University of Auckland

University of Illinois at Chicago

University of North Carolina

University of St. Andrews

Viatris

Weill Cornel Medical

About
Why New TB Drugs
R&D
Access
News

New York: 80 Pine Street, 20th floor, New York, NY 10005 • +1 212 227 7540

Johannesburg: Spaces Atrium on 5th, 9th Floor, 5th Street, Sandton, Johannesburg, 2196, South Africa • +27 12 991 6328

Press Inquiries

Jess Wiggs
p | +1 646 616 8613
e | jessica.wiggs@tballiance.org

Jobs

View job openings

Join our mailing list

Email Address

© 2025 The TB Alliance. All Rights Reserved. Report a Concern | Privacy Policy

179,697 more people will complete treatment

A sizeable portion of people receiving DR-TB treatment do not complete therapy. This is often due to the length and side effects of treatments. Those who are “lost to follow up” may remain contagious and infect others, as well as suffer increased disabilty or death. BPaL/M projects significantly lower lost to follow up rates than alternative treatments.

332,654 Additional Treatment Successes

People who do not complete treatment and/or follow-up are not considered to have successful treatment outcomes. Thus, additional treatment successes are about more than just “lives saved.” Through 2034, treating DR-TB with BPaL will result in more than 330,000 additional people with DR-TB being successfully treated.

The BPaL/M treatment costs less than $2 per day, however the vast majority of cost savings from implementing these new regimens is achieved through shorter and simpler treatment, reducing human and financial burden on health systems. This allows for the expansion of DR-TB care where costs and human resources have previously limited health systems’ capacities to treat DR-TB.

BPaL/M has shown higher treatment success rates in both trial and real world settings. Treating DR-TB with with BPaL/M instead of alternate regimens projects to save an additional 191,222 lives, globally.

Many people battling DR-TB around the world face financial hardship. TB exacerbates those hardships through lost wages while seeking treatment, repeated trips to clinics, and other related expenses. Shorter treatments with better outcomes mean additional savings for people with DR-TB.

BPaL/M is both shorter and less expensive than alternate DR-TB regimens. Length of treatment is the leading driver of cost of DR-TB treatment. The increased uptake of BPaL/M projects to result in significant cost savings for both individuals and health systems.

Tuberculosis isn’t only the world’s leading infectious cause of death; many who survive suffer long term debilitation. Short and effective DR-TB cures will result in improved quality of life for hundreds of thousands of people each year.